In a multicenter clinical trial, ghrelin receptor agonist anamorelin (ONO-7643) improved appetite, lean body mass, and body weight in advanced unresectable gastrointestinal cancer cachectic patients [211]
In a multicenter clinical trial, ghrelin receptor agonist anamorelin (ONO-7643) improved appetite, lean body mass, and body weight in advanced unresectable gastrointestinal cancer cachectic patients [211]. Advanced stages of malignancy,…